Navigation Links
EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 3, 2007 - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) today announced that Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX, is scheduled to present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Tuesday, July 10, 2007 at 1:30 p.m. (EDT) at the Mandarin Oriental Hotel in New York, NY.

The presentation will be webcast live and can be accessed on the EPIX website, www.epixpharma.com, in the investor relations section. A replay will be available approximately twenty-four hours after the presentation and will be archived on the company's website for two weeks.

About EPIX

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in development for conditions such as depression, Alzheimer's disease, cardiovascular disease and obesity. These drug candidates include PRX-08066 in Phase 2 clinical development for pulmonary hypertension associated with chronic obstructive pulmonary disease, PRX-03140 which is in a Phase 2a clinical trial in Alzheimer's disease, PRX-00023 which is in a Phase 2b clinical trial in major depressive disorder, and PRX-07034, which recently completed a Phase 1b trial and is in clinical development for the treatment of obesity and cognitive impairment. The company also has a blood-pool imaging agent (Vasovist(TM)) approved in 32 countries and marketed in Europe. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics, and Bayer Schering Pharma AG, Germany. For more information, please visit the company's website at www.epixpharma.com.

This news release contains expres
'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Proxy Statement, Schedule 14A, with the U.S. Securities & Exchange ... shareholders detailing why a "YES" vote to increase the number ... As we reflect upon the 2014 fiscal year that ...
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... presentations and satellite ... ... Board: DSCI), a provider of advanced wound care products,announced today that ... Wound & Burn Dressings with Active,Leptospermum Honey will be presented at ...
... 2 Watching your favorite player,strike out isn,t usually ... Major League Baseball (MLB) strikeouts are leading to big,wins. ... today the latest results of,the "One A Day Men,s ... this year as part of an exclusive partnership,between MLB ...
... A vaccine aimed at inducing immunity to the most common ... and more than double survival in patients, according to a ... Brain Tumor Center. , This vaccine represents a very promising ... and robs people of something most of us take for ...
... The discovery of new genetic mutations involved in ... of these common conditions, two scientists told the annual ... (Monday 2 June). , ... the Netherlands, and Dr. Eleonora Festen, from the University ...
... UC Irvine has been awarded $1.62 million to ... nontoxic alternatives to everyday products, such as electronics, plastics, ... designated the Lead Campus for a Green Materials Program, ... campuses. Oladele Ogunseitan, professor of public health and social ...
... enhanced Software Developers Kit that allows for easy ... integration to other applications, ... leading computerized maintenance management software (CMMS) provider,for the healthcare industry ... out of TMS automatically., The TMS Connect application serves ...
Cached Medicine News:Health News:Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming WUWHS Conference 2Health News:Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming WUWHS Conference 3Health News:Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming WUWHS Conference 4Health News:One A Day(R) and Major League Baseball Raise Over $106,000 to Strike Out Prostate Cancer 2Health News:One A Day(R) and Major League Baseball Raise Over $106,000 to Strike Out Prostate Cancer 3Health News:Vaccine may double survival in patients with deadly brain tumors 2Health News:Discovery of new family of genetic mutations involved in inflammatory intestinal disease 2Health News:Discovery of new family of genetic mutations involved in inflammatory intestinal disease 3Health News:UC Irvine to lead statewide program on green materials research 2Health News:Four Rivers Software Announces Enhanced Product Offering: TMS Connect(TM) 2
... 5000 mg/kg sulfate (SO 4 ) ≤ 5000 mg/kg ... mg/kg Co ≤ 5 mg/kg Cr ≤ 5 mg/kg ... ≤ 50 mg/kg Mg ≤ 5 mg/kg Mn ≤ ... mg/kg Pb ≤ 5 mg/kg Zn ≤ 5 mg/kg ...
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
Inquire...
Medicine Products: